HUP0301180A3 - Use of immidazoquinolinamines as adjuvants in dna vaccination - Google Patents
Use of immidazoquinolinamines as adjuvants in dna vaccinationInfo
- Publication number
- HUP0301180A3 HUP0301180A3 HU0301180A HUP0301180A HUP0301180A3 HU P0301180 A3 HUP0301180 A3 HU P0301180A3 HU 0301180 A HU0301180 A HU 0301180A HU P0301180 A HUP0301180 A HU P0301180A HU P0301180 A3 HUP0301180 A3 HU P0301180A3
- Authority
- HU
- Hungary
- Prior art keywords
- immidazoquinolinamines
- adjuvants
- dna vaccination
- vaccination
- dna
- Prior art date
Links
- 238000011238 DNA vaccination Methods 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0023008.6A GB0023008D0 (en) | 2000-09-20 | 2000-09-20 | Improvements in vaccination |
PCT/GB2001/004207 WO2002024225A1 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0301180A2 HUP0301180A2 (hu) | 2004-03-01 |
HUP0301180A3 true HUP0301180A3 (en) | 2005-11-28 |
Family
ID=9899764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301180A HUP0301180A3 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
Country Status (25)
Country | Link |
---|---|
US (3) | US20040076633A1 (hu) |
EP (1) | EP1318835B1 (hu) |
JP (1) | JP2004509150A (hu) |
KR (1) | KR100876263B1 (hu) |
CN (1) | CN1197620C (hu) |
AR (1) | AR035586A1 (hu) |
AT (1) | ATE401097T1 (hu) |
AU (2) | AU2001287908B2 (hu) |
BR (1) | BR0113982A (hu) |
CA (1) | CA2422863A1 (hu) |
CZ (1) | CZ2003792A3 (hu) |
DE (1) | DE60134866D1 (hu) |
ES (1) | ES2309086T3 (hu) |
GB (1) | GB0023008D0 (hu) |
HK (1) | HK1057700A1 (hu) |
HU (1) | HUP0301180A3 (hu) |
IL (1) | IL154947A0 (hu) |
MX (1) | MXPA03002453A (hu) |
MY (1) | MY138978A (hu) |
NO (1) | NO20031274L (hu) |
NZ (1) | NZ524792A (hu) |
PL (1) | PL360895A1 (hu) |
TW (1) | TWI287453B (hu) |
WO (1) | WO2002024225A1 (hu) |
ZA (1) | ZA200302231B (hu) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69932717T2 (de) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
AU2003216852B2 (en) * | 2002-03-19 | 2008-09-11 | Glaxo Group Limited | Imidazoquinolineamines as adjuvants in HIV DNA vaccination |
ATE491471T1 (de) * | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
ATE488246T1 (de) * | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort |
US7091214B2 (en) | 2002-12-20 | 2006-08-15 | 3M Innovative Properties Co. | Aryl substituted Imidazoquinolines |
US7731967B2 (en) * | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
JP2007502293A (ja) * | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ含有化合物 |
WO2005020912A2 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2005018574A2 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
EP1658076B1 (en) | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
CA2537763A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
CA2545774A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
BRPI0416936A (pt) | 2003-11-25 | 2007-01-16 | 3M Innovative Properties Co | sistemas de anel de imidazo substituìdos e métodos |
EP1701955A1 (en) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
AU2005228150A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006009826A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP1804583A4 (en) * | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | ADJUVANT FOR DNA VACCINE |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
PT1830876E (pt) * | 2004-12-30 | 2015-07-13 | Meda Ab | Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama |
JP5543068B2 (ja) * | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
ES2577514T3 (es) | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
AU2006287270A1 (en) * | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
WO2007106854A2 (en) * | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
CN101426514A (zh) * | 2006-04-25 | 2009-05-06 | 英特塞尔股份公司 | Hcv疫苗 |
US20090060928A1 (en) * | 2006-05-26 | 2009-03-05 | Jean-Claude Bystryn | Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
AU2007263281B2 (en) * | 2006-06-20 | 2012-12-06 | Transgene S.A. | Recombinant viral vaccine |
DK2032701T3 (da) | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynukleotider og polypeptider, der er inddraget i cancer |
WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
CN100450484C (zh) * | 2006-10-11 | 2009-01-14 | 北京科信必成医药科技发展有限公司 | 一种咪喹莫特混悬溶液及其凝胶剂 |
CA2677733A1 (en) | 2007-02-07 | 2008-09-25 | The Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
CA2678353A1 (en) * | 2007-02-15 | 2008-08-21 | Mannkind Corporation | A method for enhancing t cell response |
WO2009018465A1 (en) | 2007-07-31 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (kbma) protozoans with toll-like receptor agonists |
AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
MX336869B (es) | 2008-11-03 | 2016-02-04 | Alethia Biotherapeutics Inc | Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor. |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US8802433B2 (en) * | 2009-12-03 | 2014-08-12 | Aureo Co., Ltd. | Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
ES2943385T3 (es) | 2010-08-17 | 2023-06-12 | 3M Innovative Properties Company | Compuesto modificador de la respuesta inmunitaria lipidada y su uso médico |
HUE045943T2 (hu) | 2011-03-31 | 2020-02-28 | Adc Therapeutics Sa | Veseasszociált antigén 1 és antigénkötõ fragmensei elleni antitestek |
MX355623B (es) | 2011-06-03 | 2018-04-25 | 3M Innovative Properties Co | Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas. |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
AU2013209234B2 (en) | 2012-01-09 | 2017-11-09 | Adc Therapeutics Sa | Method for treating breast cancer |
GB201310578D0 (en) | 2013-06-13 | 2013-07-31 | Univ Nottingham Trent | Electroactive actuators |
EP3033056B1 (en) | 2013-08-12 | 2020-01-15 | 3M Innovative Properties Company | Peptides for enhancing transdermal delivery |
ES2906444T3 (es) | 2015-10-12 | 2022-04-18 | Reflow Medical Inc | Endoprótesis (stents) con características de suministro de medicamentos y sistemas asociados. |
WO2017184735A1 (en) * | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
JP2020533354A (ja) | 2017-09-13 | 2020-11-19 | サノフィ・パスツールSanofi Pasteur | ヒトサイトメガロウイルス免疫原性組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
WO1998017820A1 (en) * | 1996-10-23 | 1998-04-30 | American Home Products Corporation | Vaccines |
GB9818627D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
-
2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
-
2001
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en active IP Right Grant
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active IP Right Cessation
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 EP EP01967535A patent/EP1318835B1/en not_active Revoked
-
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
- 2003-11-26 HK HK03108643.1A patent/HK1057700A1/xx not_active IP Right Cessation
-
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1318835A1 (en) | 2003-06-18 |
MXPA03002453A (es) | 2003-06-19 |
US20110002953A1 (en) | 2011-01-06 |
HUP0301180A2 (hu) | 2004-03-01 |
NZ524792A (en) | 2004-09-24 |
AR035586A1 (es) | 2004-06-16 |
IL154947A0 (en) | 2003-10-31 |
AU8790801A (en) | 2002-04-02 |
ATE401097T1 (de) | 2008-08-15 |
CA2422863A1 (en) | 2002-03-28 |
EP1318835B1 (en) | 2008-07-16 |
BR0113982A (pt) | 2003-08-19 |
PL360895A1 (en) | 2004-09-20 |
DE60134866D1 (de) | 2008-08-28 |
AU2001287908B2 (en) | 2005-06-30 |
TWI287453B (en) | 2007-10-01 |
KR100876263B1 (ko) | 2008-12-26 |
MY138978A (en) | 2009-08-28 |
CN1473051A (zh) | 2004-02-04 |
US20070248614A1 (en) | 2007-10-25 |
NO20031274L (no) | 2003-05-19 |
ZA200302231B (en) | 2004-05-05 |
US20040076633A1 (en) | 2004-04-22 |
NO20031274D0 (no) | 2003-03-19 |
CN1197620C (zh) | 2005-04-20 |
GB0023008D0 (en) | 2000-11-01 |
HK1057700A1 (en) | 2004-04-16 |
CZ2003792A3 (cs) | 2004-12-15 |
JP2004509150A (ja) | 2004-03-25 |
WO2002024225A1 (en) | 2002-03-28 |
ES2309086T3 (es) | 2008-12-16 |
KR20040023566A (ko) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU8790801A (en) | Use of immidazoquinolinamines as adjuvants in dna vaccination | |
HUP0204250A3 (en) | Use of hiv-protein or -polynucleotide for vaccine produce | |
GB0020953D0 (en) | Vaccine | |
HUP0301043A3 (en) | Vaccine | |
IL155072A0 (en) | Vaccine | |
AP2002002700A0 (en) | Vaccine composition | |
AU1591402A (en) | Vaccine | |
HK1056884A1 (en) | Purification of hbv antigens for use in vaccines | |
IL174325A0 (en) | Dna vaccine compositions and methods of use | |
GB0014288D0 (en) | Vaccine | |
EP1335953A4 (en) | POLYNUCLEOTIDE VACCINE ADJUVANTS AND FORMULATIONS CONTAINING CATIONIC SURFACTANTS, METHODS OF USE THEREOF | |
GB0105606D0 (en) | Immunogens and vaccines and their preparation and use | |
GB0025694D0 (en) | Vaccine | |
GB0003082D0 (en) | Vaccine | |
GB0006693D0 (en) | Vaccine | |
GB0015935D0 (en) | Vaccine | |
GB0027644D0 (en) | Fish vaccine | |
GB0031218D0 (en) | Metgod of vaccine preparation | |
AUPR042100A0 (en) | Vaccines and methods of vaccination | |
GB0008029D0 (en) | New vaccine formulations | |
GB0016686D0 (en) | Novel vaccine | |
GB0022991D0 (en) | Vaccine | |
GB0015747D0 (en) | Vaccine | |
GB0015736D0 (en) | Vaccine | |
GB0018602D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |